STOCK TITAN

Plus Therapeutics to Present at the virtual Fall Investor Summit on November 16th-18th

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Plus Therapeutics (NASDAQ:PSTV), is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets, including recurrent glioblastoma. PSTV will be presenting at this year's virtual Fall Investor Summit on November 16th-18th.

The Fall Investor Summit will take place virtually, featuring 75 companies and over 300 institutional and retail investors.

About Plus Therapeutics

Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found atplustherapeutics.com andrespect-trials.com.

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.

To register as a presenting company: please contact Brittney Blocker (brittney@investorsummitgroup.com)

To request complimentary investor registration: please visit our website at www.investorsummitgroup.com

News Compliments of ACCESSWIRE

FOR MORE INFORMATION

Please visit: www.investorsummitgroup.com

Or, contact Brittney Blocker at brittney@investorsummitgroup.com

SOURCE: Plus Therapeutics



View source version on accesswire.com:
https://www.accesswire.com/615981/Plus-Therapeutics-to-Present-at-the-virtual-Fall-Investor-Summit-on-November-16th-18th

PLUS THERAPEUTICS, Inc.

NASDAQ:PSTV

PSTV Rankings

PSTV Latest News

PSTV Stock Data

9.75M
4.21M
1.45%
3.27%
1.07%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
AUSTIN

About PSTV

plus therapeutics, inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. its lead product candidate is doceplus, a protein-stabilized pegylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. the company is also involved in developing doxoplus, a generic pegylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and kaposi's sarcoma. it has a license agreement with nanotx, corp. to develop and commercialize nanotx's glioblastoma treatment. the company was formerly known as cytori therapeutics, inc. and changed its name to plus therapeutics, inc. in july 2019. plus therapeutics, inc. was founded in 1996 and is headquartered in austin, texas.